TIDMHZD
RNS Number : 3352O
Horizon Discovery Group plc
29 January 2019
Horizon Discovery Group plc
Appointment of Chief Financial Officer
Cambridge, UK, 29 January 2019: Horizon Discovery Group plc
(LSE: HZD) ("Horizon" or "the Group" or "Company"), a global leader
in the application of gene editing and gene modulation
technologies, today announces the appointment of Jayesh Pankhania
as Chief Financial Officer ("CFO") and member of the Board of
Horizon effective immediately. Jayesh will succeed Richard
Vellacott who is stepping down from the role and the Board today
following almost seven valuable years of service at Horizon.
Richard will continue with the Company in an advisory capacity for
a period to time to facilitate a smooth transition.
Jayesh joined Horizon Discovery's Finance department in April
2018 in an interim CFO capacity. Prior to joining Horizon, Jayesh
was Group CFO of Xtera Ltd where he was responsible for developing
business plans and strategies for growth. Previous leadership roles
include Deputy CFO of Asia Resource Minerals Plc, CFO of Planned
Maintenance at Carillion Plc. and CFO of Rail and Metro at Serco
Plc. Cumulatively, Jayesh has more than 25 years' of blue chip
international finance experience, including working within Main
Market listed companies. He has deep expertise in providing
financial leadership to growing businesses, building
high-performing finance teams with the highest levels of corporate
and financial governance, and working in partnership with
management teams and Boards to develop and deliver robust business
strategies. Jayesh is a qualified Chartered Accountant and holds an
MBA from London Business School.
Richard Vellacott joined Horizon in July 2012. During his tenure
Richard has worked as CFO, COO, deputy CEO and interim CEO. Richard
led the business, as CFO, through the successful public listing on
the AIM market, fundraisings including the $80 million financing in
2017 and four international acquisitions.
Terry Pizzie, Chief Executive Officer of Horizon Discovery,
commented: "I'm very pleased to welcome Jayesh as CFO of the Group
at this exciting time. In his role as interim CFO, Jayesh's
leadership of the finance function and his support to the
management team were very quickly apparent and invaluable as we
reviewed our business priorities and implemented a five-year
investment plan. His proven financial experience, including with
listed companies, will be an asset to the Group as we move to the
next level and continue to progress our vision and growth plans for
the business.
"I would like to express my sincere gratitude to Richard, on
behalf of Horizon's Board, management team and staff, for his
contribution to the growth of the Group since 2012."
Jayesh Pankhania, Chief Financial Officer of Horizon Discovery,
said: "From the time I arrived at Horizon I was deeply impressed by
the quality of people and the Group's market leading capabilities
in gene editing and gene modulation. I look forward to working
closely with Terry, the management team and the Board as we
continue to invest in our key strategic priorities whilst
maintaining operational efficiency, in order to successfully
execute on the Group's next stage of growth."
The following information regarding the appointment of Jayesh
Pankhania, aged 48, is disclosed in accordance with Rule 17 and
paragraph (g) of Schedule 2 of the AIM rules.
Current directorships/ partnerships:
Nisaba Limited
Ealing Mencap
Previous directorships/ partnerships held in the past five
years:
Vallar Investments UK Limited
Asia Coal Resources Limited
ENDS
For further information from Horizon Discovery Group plc, please
contact:
Horizon Discovery Group plc
Terry Pizzie, Chief Executive Officer
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield / Duncan Monteith
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world
leader in gene editing and gene modulation technologies. Horizon
designs and engineers cells using its translational genomics
platform, a highly precise and flexible suite of DNA editing tools
(rAAV, ZFN, CRISPR, Transposon and base editing) and, following the
acquisition of Dharmacon, Inc., its functional genomics platform
comprising gene knockdown (RNAi) and gene expression (cDNA, ORF)
tools, for research and clinical applications that advance human
health. Horizon's platforms and capabilities enable researchers to
alter almost any gene or modulate its function in human or
mammalian cell-lines.
Horizon offers an extensive range of catalogue products and
related research services to support a greater understanding of the
function of genes across all species and the genetic drivers of
human disease and the development of personalised molecular, cell
and gene therapies. These have been adopted by over 10,000
academic, drug discovery, drug manufacturing and clinical
diagnostics customers around the globe, as well as in the Company's
own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the ticker HZD
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAKMGZMGRKGLZZ
(END) Dow Jones Newswires
January 29, 2019 02:00 ET (07:00 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2023 to Apr 2024
